Exploring the Role of Target Expression in Treatment Efficacy of Antibody–Drug Conjugates (ADCs) in Solid Cancers: A Comprehensive Review-Reference-Cited by-同舟云学术

Exploring the Role of Target Expression in Treatment Efficacy of Antibody–Drug Conjugates (ADCs) in Solid Cancers: A Comprehensive Review

Published:2024-07-27 Issue: Volume: Page:
ISSN:1523-3790
Container-title:Current Oncology Reports
language:en
Short-container-title:Curr Oncol Rep

Author:

Mathiot Laurent,Baldini Capucine,Letissier Octave,Hollebecque Antoine,Bahleda Rastislav,Gazzah Anas,Smolenschi Cristina,Sakkal Madona,Danlos François-Xavier,Henon Clémence,Beshiri Kristi,Goldschmidt Vincent,Parisi Claudia,Patrikidou Anna,Michot Jean-Marie,Marabelle Aurélien,Postel-Vinay Sophie,Bernard-Tessier Alice,Loriot Yohann,Ponce Santiago,Champiat Stéphane,Ouali Kaïssa

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s11912-024-01576-9.pdf

Reference93 articles.

1. Alley SC, Okeley NM, Senter PD. Antibody–drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol. 2010;14(4):529–37.

2. Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18(6):327–44.

3. Yu J, Song Y, Tian W. How to select IgG subclasses in developing anti-tumor therapeutic antibodies. J Hematol OncolJ Hematol Oncol. 2020;13(1):45.

4. Lopus M, Oroudjev E, Wilson L, Wilhelm S, Widdison W, Chari R, et al. Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules. Mol Cancer Ther. 2010;9(10):2689–99.

5. Akaiwa M, Dugal-Tessier J, Mendelsohn BA. Antibody-Drug Conjugate Payloads; Study of Auristatin Derivatives. Chem Pharm Bull (Tokyo). 2020;68(3):201–11.